GlaxoSmithKline intends to price notes due 2023 via four bookrunners

By Devika Patel

Knoxville, Tenn., Sept. 28 – GlaxoSmithKline Capital plc plans to offer dollar-denominated notes due 2023, according to a 424B2 filed with the Securities and Exchange Commission.

The notes will be guaranteed by Brentford, England-based GlaxoSmithKline plc.

The notes feature a make-whole call and then a par call.

BofA Securities Inc., Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC and Morgan Stanley & Co. LLC are the bookrunners.

Proceeds will be used to redeem the company’s 3.125% notes due 2021 and for general corporate purposes.

The global health care company for pharmaceuticals and consumer health products has its U.S. headquarters in Wilmington, Del.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.